Oppenheimer Cuts Price Target on United Rentals (URI) Following 2Q15 Results and Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
RBC Capital Downgrades United Rentals (URI) to Outperform
July 24, 2015 7:05 AM EDTRBC Capital downgraded United Rentals (NYSE: URI) from Top Pick to Outperform with a price target of $94.00 (from $110.00).
For an analyst ratings summary and ratings history on United Rentals click here. For more ratings news on United Rentals click here.
Shares of United Rentals closed at $66.98 yesterday.
... MoreNotable 52-Week Highs and Lows 7/23: (ITEK) (HBAN) (FTNT) High; (URI) (UNP) (CAB) Low
July 23, 2015 3:48 PM EDT52-Week High:Inotek Pharmaceuticals (Nasdaq: ITEK) $16.75. Inotek Pharmaceuticals ripping higher Thursday after the company announced the Phase 3 development strategy of its lead glaucoma drug, trabodenoson, a first-in-class selective adenosine mimetic designed to restore the eyes natural pressure control mechanism. Based on feedback from a recent End of Phase 2 meeting with the US Food and Drug Administration (FDA), Inotek is in final preparation stages to commence its first Phase 3 trial to support a New Drug Application (NDA) for trabodenoson.
Pre-Open Stock Movers 07/23: (CARA) (SNDK) (CRUS) Higher; (CVA) (URI) (SCSS) Lower (more...)
July 23, 2015 9:30 AM EDTInotek Pharmaceuticals Corporation (NASDAQ: ITEK) 51% HIGHER; announced the Phase 3 development strategy of its lead glaucoma drug, trabodenoson, a first-in-class selective adenosine mimetic designed to restore the eyes natural pressure control mechanism. Based on... More
